ABBVIE INC 4.25 percent 14Nov2028 is a Senior Unsecured Note issued by the corporate entity on the 13th of September 2018. ABBVIE is trading at 99.29 as of the 25th of February 2025, a 0.31% up since the beginning of the trading day. The bond's open price was 98.98. ABBVIE has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Ratings for ABBVIE INC 425 are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
AbbVie Inc. is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVies portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolicshormones products, virology products, endocrinology products, dyslipidemia products and other products. More on ABBVIE INC 425
Our tools can tell you how much better you can do entering a position in ABBVIE without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Sectors Now
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
ABBVIE financial ratios help investors to determine whether ABBVIE Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABBVIE with respect to the benefits of owning ABBVIE security.